CADRE's educational activities are funded from many sources, including Amylin Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly & Company, GlaxoSmithKline, LifeScan, Merck & Co., Novartis, Novo Nordisk, Nutrition 21, Pfizer Inc., Sankyo Pharma, and sanofi-aventis. 

• CADRE's Current Diabetes Practice - The CADRE newsletter
  The current issue contains information on obesity and type 2 diabetes, as well as an update on continuing medical education
  Read archived issues
• Evolution of Insulin Therapy: Past, Current, and Future Strategies
  CME webcast of the CADRE symposium at the 2007 ADA Annual Meeting (CME opportunity expires 12/13/08)
• Where Do Incretin Therapies Fit in the Type 2 Diabetes Treatment Algorithm? 
  Up-to-date, case-based discussion of incretin therapy (Issue 2, 2007; CME opportunity expires 6/22/08)
• Case Study: A 57-Year-Old Obese Native American Man 
  Incretin therapy and the ADA/EASD Algorithm for Type 2 Diabetes (CME opportunity expires 4/27/08)
• Self-monitoring of Blood Glucose 
  CADRE's diabetes slide kit on the importance of SMBG in achieving optimal glycemic control
• Debating the Management of Type 2 Diabetes With Emerging Therapies 
  Webcast of the CADRE symposium at the 2006 ADA Annual Meeting  (CME opportunity expires 2/22/08)